Menu

RegMedNet

  • Visit /
  • Register
  • Sign In

Content matching 'kymriah'

Cell therapy weekly: more indications for Kymriah
Member Exclusive NEWS ROUND-UP
News & views, Cell therapy

Cell therapy weekly: more indications for Kymriah

Go to the profile of RegMedNet
RegMedNet
Jan 18, 2018
Kymriah and Yescarta recommended for EU approval
News & views, Spotlight on immunotherapy, Cell therapy, CAR-T, UK and Europe

Kymriah and Yescarta recommended for EU approval

Go to the profile of RegMedNet
RegMedNet
Jul 03, 2018
Cell therapy weekly: Novartis faces production glitch over Kymriah
NEWS ROUND-UP
News & views, Spotlight on immunotherapy, Cell therapy, FDA, UK and Europe, US and Canada, Asia and the rest of the world

Cell therapy weekly: Novartis faces production glitch over Kymriah

Go to the profile of RegMedNet
RegMedNet
Jul 19, 2018
NICE approves Kymriah for use in adults following commercial agreement with NHS England
News & views, Cell therapy, Ethics & policy

NICE approves Kymriah for use in adults following commercial agreement with NHS England

Go to the profile of Freya Leask
Freya Leask
Feb 01, 2019
Kymriah is first CAR-T therapy to be made available on the NHS
Spotlight on immunotherapy, Cell therapy, Ethics & policy, CAR-T

Kymriah is first CAR-T therapy to be made available on the NHS

Go to the profile of RegMedNet
RegMedNet
Sep 05, 2018
Cell therapy weekly: Kymriah could be available in Japan and stem cells show benefits against multiple sclerosis
NEWS ROUND-UP
News & views, Spotlight on immunotherapy, Cell therapy, Clinical trials, Research, CAR-T, UK and Europe, US and Canada, Asia and the rest of the world

Cell therapy weekly: Kymriah could be available in Japan and stem cells show benefits against multiple sclerosis

Go to the profile of RegMedNet
RegMedNet
Apr 26, 2018
Cell therapy weekly: Yescarta “is not recommended” for NHS availability
Member Exclusive
Cell therapy, Ethics & policy, Industry developments, CAR-T, UK and Europe, US and Canada

Cell therapy weekly: Yescarta “is not recommended” for NHS availability

Go to the profile of RegMedNet
RegMedNet
Aug 30, 2018
Cell therapy weekly: New hurdle in immunotherapy development
Member Exclusive NEWS ROUND-UP
Spotlight on immunotherapy, Cell therapy, Ethics & policy, Research

Cell therapy weekly: New hurdle in immunotherapy development

Go to the profile of RegMedNet
RegMedNet
Sep 20, 2018
Cenk Sumen (Thermo Fisher Scientific) on the 'durability' of cell & gene therapies

Cenk Sumen (Thermo Fisher Scientific) on the 'durability' of cell & gene therapies

Go to the profile of Shiraz Ziya
Shiraz Ziya
Sep 03, 2018
Welcome to our spotlight on immunotherapy!
Spotlight on immunotherapy

Welcome to our spotlight on immunotherapy!

Go to the profile of RegMedNet
RegMedNet
Sep 01, 2018
Shanghai venture will bring advanced cell therapies to China
Events

Shanghai venture will bring advanced cell therapies to China

Go to the profile of Freya Leask
Freya Leask
Sep 28, 2018
NHS England strikes deal for ground-breaking CAR-T therapy in a new European first
Member Exclusive
News & views, Cell therapy, Ethics & policy

NHS England strikes deal for ground-breaking CAR-T therapy in a new European first

Go to the profile of Jasmine Harris
Jasmine Harris
Oct 08, 2018
Cell therapy weekly: StemGenex receives warning letter from FDA over unapproved cell therapy and facility with “significant violations”
Member Exclusive NEWS ROUND-UP
Cell therapy, Clinical trials, Ethics & policy

Cell therapy weekly: StemGenex receives warning letter from FDA over unapproved cell therapy and facility with “significant violations”

Go to the profile of RegMedNet
RegMedNet
Nov 15, 2018
The Cell Manufacturing Imperative
Member Exclusive COMMUNITY POST
News & views, Spotlight on commercialization and translation, Cell therapy, Manufacturing

The Cell Manufacturing Imperative

Go to the profile of RegMedNet
RegMedNet
Oct 19, 2017
Cell therapy special: best of 2018
NEWS ROUND-UP
News & views, Cell therapy, Gene editing, UK and Europe, US and Canada, Asia and the rest of the world

Cell therapy special: best of 2018

Go to the profile of RegMedNet
RegMedNet
Dec 13, 2018
Event preview: CAR-TCR Summit Europe
Member Exclusive
Events

Event preview: CAR-TCR Summit Europe

Go to the profile of RegMedNet
RegMedNet
Dec 19, 2017
Cell therapy weekly: CAR influence on T-cells key to improving immunotherapy
NEWS ROUND-UP
News & views, Spotlight on immunotherapy, Cell therapy, Research, CAR-T, UK and Europe, US and Canada

Cell therapy weekly: CAR influence on T-cells key to improving immunotherapy

Go to the profile of RegMedNet
RegMedNet
Aug 23, 2018
Raw materials considerations for GMP manufacturing: an interview with Bernd Leistler, CellGenix GmbH
Cell therapy, Clinical trials, UK and Europe, US and Canada

Raw materials considerations for GMP manufacturing: an interview with Bernd Leistler, CellGenix GmbH

Go to the profile of RegMedNet
RegMedNet
May 01, 2018
Optimizing the quality of cell therapy starting materials
Cell therapy

Optimizing the quality of cell therapy starting materials

Go to the profile of Hemacare
Hemacare
Oct 01, 2018

Users matching 'kymriah'

  • Acceptable Use Policy
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Report Content
Copyright © 2019 Future Science Group All rights reserved. Powered by Zapnito.
RegMedNet
RegMedNet
  • Home
  • Webinars
  • Channels
    • Back
    • Features
      • Back
      • Ask the experts
      • In focus
      Spotlights
      • Back
      • Spotlight on immunotherapy
      • Spotlight on MSCs
      • Spotlight on organoids
      • Spotlight on commercialization and translation
      • Spotlight on cell therapy regulation
      • Spotlight on iPSC production
      • Spotlight on biomaterials
      • Spotlight on wound healing
    • Biobanking
    • Cell therapy
    • Clinical trials
    • Ethics & policy
    • Industry developments
    • Manufacturing
    • Events
    • Research
    • RegMedNet
    • Regenerative Medicine
  • Rooms
  • Q & A
  • Community
    • Back
    • Editors
    • Leaders
  • Organisations
    • Back
    • Partners
  • About RegMedNet
  • About the Journal
  • About the Publisher
  • Community Guidelines
  • Sponsorship
  • RegMedNet how-to guide
  • RegMedNet FAQs
  • Social
  • Facebook
  • Twitter
  • LinkedIn
We use cookies to help improve your experience. By continuing to browse our website you are consenting to our use of cookies.
Learn more